Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

BACKGROUND: The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for efficacy and superiority for major bleeding. Owing to differences in targeted anticoa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Norikazu, Hirayama, Atsushi, Maeda, Hideaki, Sakagami, Satoru, Shikata, Hiroo, Prins, Martin H, Lensing, Anthonie WA, Kato, Masaharu, Onuma, Junichi, Miyamoto, Yuki, Iekushi, Kazuma, Kajikawa, Mariko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Original Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339301/
https://www.ncbi.nlm.nih.gov/pubmed/25717286
http://dx.doi.org/10.1186/s12959-015-0035-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339301/
https://www.ncbi.nlm.nih.gov/pubmed/25717286
http://dx.doi.org/10.1186/s12959-015-0035-3

Ejemplares similares